
Dynavax Technologies (DVAX) Stock Forecast & Price Target
Dynavax Technologies (DVAX) Analyst Ratings
Bulls say
Dynavax Technologies Corp is experiencing positive developments with its vaccine candidates, particularly the shingles vaccine Z-1018, which shows vaccine response rates (VRR) comparable to those of Shingrix, but with significantly better tolerability. The encouraging results regarding CD4+ T-cell responses and tolerability for Z-1018 align well with the company’s goals for immunogenicity, indicating a strong potential for market acceptance. Furthermore, Dynavax continues to generate substantial revenue from its existing products, CpG 1018 and HEPLISAV-B, supporting a robust financial foundation as it advances its pipeline.
Bears say
Dynavax Technologies Corp faces significant risks related to its clinical development pipeline, as potential candidates may not meet efficacy endpoints or could present safety issues, jeopardizing their approval and commercialization. Furthermore, the company may encounter challenges in effectively commercializing its proprietary candidates due to unfavorable market conditions, strong competition, or internal factors, which could further hinder future revenue generation. Additionally, the possibility of not securing acceptable partnership terms for its candidates adds another layer of risk, threatening the successful launch and adoption of its products.
This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.
Dynavax Technologies (DVAX) Analyst Forecast & Price Prediction
Start investing in Dynavax Technologies (DVAX)
Order type
Buy in
Order amount
Est. shares
0 shares